Long-Term Success of Gene Therapy for ADA-SCID in Children

A groundbreaking gene therapy developed by researchers at the University College London (UCL), Great Ormond Street Hospital (GOSH), and the University of California, Los Angeles (UCLA) has shown remarkable success in treating children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), a rare and life-threatening genetic disorder. The therapy, which modifies a child's own blood stem cells to restore immune function, has been followed up for an average of 7.5 years in a cohort of 62 patients treated between 2012 and 2019. The results indicate a 100% survival rate, with 95% of the children cured of their condition.

Landmark gene therapy study shows safety for childrenGene therapy delivers lasting immune protection in children with rare disorderGene Therapy Provides Long-Term Immune Protection for Children with RareADA-SCID Gene Therapy: Children Remain Cured After 10+ YearsUsNews and World ReportNine-year-old Laois boy’s ‘landmark’ gene therapy treatment has ‘life-changing’ resultsBreakingNews.ie

ADA-SCID is caused by mutations in the ADA gene, leading to a deficiency of the enzyme necessary for immune function. The new gene therapy involves harvesting a child's hematopoietic stem cells, modifying them with a lentiviral vector to insert a healthy copy of the ADA gene, and then reinfusing these corrected cells back into the patient. This process allows the body to produce functional immune cells capable of combating infections. The immune system typically takes six to twelve months to fully reconstitute after treatment.

Gene Therapy Provides Long-Term Immune Protection for Children with RareADA-SCID Gene Therapy: Children Remain Cured After 10+ YearsGene therapy delivers lasting immune protection in children with rare disorderNBC NewsUsNews and World ReportLandmark gene therapy study shows safety for children

The study reported that all 62 children are alive today, with 59 experiencing restored immune function without the need for additional treatments. The follow-up data, representing 474 years of patient observation, revealed no serious complications related to the gene therapy itself. Most adverse effects were mild and associated with preparatory chemotherapy rather than the gene therapy. Notably, the therapy has allowed treated children to receive routine vaccinations, which was previously impossible due to their compromised immune systems.

Landmark gene therapy study shows safety for children

Eliana Nachem, diagnosed with ADA-SCID at three months old, received the gene therapy at ten months and has since thrived, attending school and participating in sports. Her mother, Caroline, described the treatment as a "rebirth," allowing Eliana to lead a normal life after years of isolation. Similarly, Andy Cash, diagnosed at three weeks, underwent the same treatment and is now a vibrant nine-year-old, actively participating in boxing and social activities.

NBC News

The research team is now preparing to seek FDA approval for the gene therapy, with hopes to make it widely accessible to children with ADA-SCID. The therapy's success has prompted discussions about market authorization in the UK, which would facilitate broader access to this innovative treatment. The ability to freeze the modified stem cells for later use is expected to enhance accessibility, allowing for local collection and processing of cells.

Gene Therapy Provides Long-Term Immune Protection for Children with Rare

While the results are promising, challenges remain in the commercialization of gene therapies for rare diseases like ADA-SCID. The high costs associated with production and regulatory compliance may limit availability. Experts emphasize the need for sustainable solutions to ensure that effective treatments reach all patients in need.

An experimental therapy saves the lives of more than 60 children with a deadly disease

The long-term data from this gene therapy trial represent a significant advancement in the treatment of ADA-SCID, offering hope for children afflicted by this condition. As the research team moves toward regulatory approval, the success of this therapy could pave the way for similar approaches to other genetic disorders, transforming the landscape of pediatric medicine.

Gene Therapy Provides Long-Term Immune Protection for Children with Rare